NASDAQ:CLVS

Clovis Oncology Stock Forecast, Price & News

$4.86

-0.16 (-3.19 %)

(As of 07/23/2021 12:00 AM ET)

Add

Compare

Today's Range

$4.85

▼

$5.05

50-Day Range

$4.86

▼

$6.54

52-Week Range

$4.08

▼

$11.10

Volume3.48 million shs

Average Volume9.30 million shs

Market Capitalization$508.19 million

P/E RatioN/A

Dividend YieldN/A

Beta1.66

30 days | 90 days | 365 days | Advanced Chart

Receive CLVS News and Ratings via Email

Sign-up to receive the latest news and ratings for Clovis Oncology and its competitors with MarketBeat's FREE daily newsletter.

About Clovis Oncology

Clovis Oncology, Inc, a biopharmaceutical company, focuses on acquiring, developing, and commercializing anti-cancer agents in the United States, Europe, and internationally. Its commercial product includes Rubraca (rucaparib) tablet, a small molecule poly ADP-ribose polymerase inhibitor, used as monotherapy for the treatment of patients with deleterious BRCA mutation associated advanced ovarian cancer, who have been treated with two or more chemotherapies, and selected for therapy by an FDA-approved companion diagnostic for Rubraca. As of 4/6/18, Rubraca® (rucaparib) is also approved by the FDA for the maintenance treatment of adult patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in a complete or partial response to platinum-based chemotherapy. FDA granted regular approval for Rubraca in this second, broader and earlier-line indication on a priority review timeline based on positive data from the phase 3 ARIEL3 clinical trial. Biomarker testing is not required for patients to be prescribed Rubraca in this maintenance treatment indication.

Clovis Oncology to Announce Second Quarter 2021 Financial Results and Host Webcast Conference Call on August 4
July 21, 2021 | finance.yahoo.com

Thinking about buying stock in Ashford Hospitality Trust, Clovis Oncology, Exela Technologies, Wipro, or Atossa Therapeutics?
July 14, 2021 | marketwatch.com

Clovis Oncology (NASDAQ:CLVS) Trading Up 4.4%
July 14, 2021 | americanbankingnews.com

Clovis Oncology, Inc. Common Stock (CLVS)
July 12, 2021 | nasdaq.com

Clovis Oncology Appoints Dr. Ronit Simantov to its Board of Directors
July 12, 2021 | finance.yahoo.com

What's Going On With Clovis Oncology Stock?
July 12, 2021 | msn.com

Clovis Oncology (NASDAQ:CLVS) Shares Gap Up to $5.42
July 12, 2021 | americanbankingnews.com

Clovis Oncology (NASDAQ:CLVS) Expected to Announce Quarterly Sales of $40.81 Million
July 10, 2021 | americanbankingnews.com

Clovis Oncology (NASDAQ:CLVS) Stock Price Down 1.9%
July 9, 2021 | americanbankingnews.com

Clovis Oncology (NASDAQ:CLVS) Expected to Announce Earnings of -$0.57 Per Share
July 8, 2021 | americanbankingnews.com

See More Headlines

Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Sub-IndustryBiotechnology
SectorMedical
Current SymbolNASDAQ:CLVS
Previous Symbol
CUSIP18946410
CIK1466301
Webwww.clovisoncology.com
Phone303-625-5000
EmployeesN/A
Year FoundedN/A

Sales & Book Value

Annual Sales$164.52 million
Price / Sales3.09
Cash FlowN/A
Price / Cash FlowN/A
Book Value($1.80) per share
Price / Book-2.70

Profitability

EPS (Most Recent Fiscal Year)($3.92)
Net Income$-369,210,000.00
Net Margins-210.08%
Return on EquityN/A
Return on Assets-51.46%

Debt

Price-To-Earnings

Miscellaneous

Outstanding Shares104,565,000
Market Cap$508.19 million
Next Earnings Date8/4/2021 (Confirmed)
OptionableOptionable

MarketRank^™

Overall MarketRank^™

1.39 out of 5 stars

Medical Sector

762nd out of 2,214 stocks

Pharmaceutical Preparations Industry

368th out of 867 stocks

3.0 Analyst's Opinion

Consensus Rating
Clovis Oncology has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on 1 buy rating, 2 hold ratings, and 1 sell rating.
Price Target Upside/Downside
According to analysts' consensus price target of $6.67, Clovis Oncology has a forecasted upside of 37.2% from its current price of $4.86.
Amount of Analyst Coverage
Clovis Oncology has only been the subject of 1 research reports in the past 90 days.

2.5 Community Rank

Outperform Votes
Clovis Oncology has received 578 “outperform” votes. (Add your “outperform” vote.)
Underperform Votes
Clovis Oncology has received 562 “underperform” votes. (Add your “underperform” vote.)
Community Sentiment
Clovis Oncology has received 50.70% “outperform” votes from our community.

MarketBeat's community ratings are surveys of what our community members think about Clovis Oncology and other stocks. Vote “Outperform” if you believe CLVS will outperform the S&P 500 over the long term. Vote “Underperform” if you believe CLVS will underperform the S&P 500 over the long term. You may vote once every thirty days.

0.0 Dividend Strength

Dividend Yield
Clovis Oncology does not currently pay a dividend.
Dividend Growth
Clovis Oncology does not have a long track record of dividend growth.

0.8 Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Clovis Oncology insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $23,195.00 in company stock.
Percentage Held by Insiders
Only 8.30% of the stock of Clovis Oncology is held by insiders.
Percentage Held by Institutions
47.84% of the stock of Clovis Oncology is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.6 Earnings and Valuation

Earnings Growth
Earnings for Clovis Oncology are expected to grow in the coming year, from ($2.32) to ($1.30) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Clovis Oncology is -1.31, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Clovis Oncology is -1.31, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

See Top Rated MarketRank™ Stocks Here

Clovis Oncology (NASDAQ:CLVS) Frequently Asked Questions

Is Clovis Oncology a buy right now?

4 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Clovis Oncology in the last twelve months. There are currently 1 sell rating, 2 hold ratings and 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "hold" Clovis Oncology stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in CLVS, but not buy additional shares or sell existing shares.
View analyst ratings for Clovis Oncology or view top-rated stocks.

What stocks does MarketBeat like better than Clovis Oncology?

Wall Street analysts have given Clovis Oncology a "Hold" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Clovis Oncology wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

When is Clovis Oncology's next earnings date?

Clovis Oncology is scheduled to release its next quarterly earnings announcement on Wednesday, August 4th 2021.
View our earnings forecast for Clovis Oncology.

How can I listen to Clovis Oncology's earnings call?

Clovis Oncology will be holding an earnings conference call on Wednesday, August 4th at 8:30 AM Eastern. Interested parties can register for or listen to the call using this link.

How were Clovis Oncology's earnings last quarter?

Clovis Oncology (NASDAQ:CLVS) announced its earnings results on Wednesday, May, 5th. The biopharmaceutical company reported ($0.64) earnings per share for the quarter, beating the Thomson Reuters' consensus estimate of ($0.72) by $0.08. The biopharmaceutical company had revenue of $38.05 million for the quarter, compared to the consensus estimate of $44.84 million.
View Clovis Oncology's earnings history.

How has Clovis Oncology's stock price been impacted by Coronavirus?

Clovis Oncology's stock was trading at $6.17 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, CLVS shares have decreased by 21.2% and is now trading at $4.86.
View which stocks have been most impacted by COVID-19.

What price target have analysts set for CLVS?

4 equities research analysts have issued 12-month target prices for Clovis Oncology's shares. Their forecasts range from $3.00 to $12.00. On average, they expect Clovis Oncology's stock price to reach $6.67 in the next year. This suggests a possible upside of 37.2% from the stock's current price.
View analysts' price targets for Clovis Oncology or view top-rated stocks among Wall Street analysts.

Who are Clovis Oncology's key executives?

Clovis Oncology's management team includes the following people:

Mr. Patrick J. Mahaffy MA, Co-Founder, Chief Exec. Officer, Pres and Exec. Director (Age 55)
Dr. Gillian C. Ivers-Read BSc, Co-Founder, Chief Regulatory Officer and Exec. VP of Technical Operations (Age 64)
Mr. Daniel W. Muehl CPA, Sr. VP of Fin. and Principal Financial & Accounting Officer (Age 54)
Dr. Lindsey Rolfe BSc, MB ChB, MRCP, FFPM, Chief Medical Officer and Exec. VP of Clinical, Preclinical Devel. & Pharmacovigilance (Age 50)
Mr. Corwin Dale Hooks, Chief Commercial Officer and Sr. VP (Age 51)

What is Patrick J. Mahaffy's approval rating as Clovis Oncology's CEO?

12 employees have rated Clovis Oncology CEO Patrick J. Mahaffy on Glassdoor.com. Patrick J. Mahaffy has an approval rating of 49% among Clovis Oncology's employees. This puts Patrick J. Mahaffy in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies.

Who are some of Clovis Oncology's key competitors?

Some companies that are related to Clovis Oncology include Amgen (AMGN), Gilead Sciences (GILD), Regeneron Pharmaceuticals (REGN), Vertex Pharmaceuticals (VRTX), Biogen (BIIB), Alexion Pharmaceuticals (ALXN), Seagen (SGEN), Alnylam Pharmaceuticals (ALNY), Exact Sciences (EXAS), Incyte (INCY), Novavax (NVAX), BioMarin Pharmaceutical (BMRN), Repligen (RGEN), Neurocrine Biosciences (NBIX) and United Therapeutics (UTHR).
View all of CLVS's competitors.

What other stocks do shareholders of Clovis Oncology own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Clovis Oncology investors own include Gilead Sciences (GILD), Micron Technology (MU), NVIDIA (NVDA), Advanced Micro Devices (AMD), Inovio Pharmaceuticals (INO), Tesla (TSLA), Amarin (AMRN), Intercept Pharmaceuticals (ICPT), Netflix (NFLX) and Alibaba Group (BABA).

What is Clovis Oncology's stock symbol?

Clovis Oncology trades on the NASDAQ under the ticker symbol "CLVS."

How do I buy shares of Clovis Oncology?

Shares of CLVS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Clovis Oncology's stock price today?

One share of CLVS stock can currently be purchased for approximately $4.86.

How much money does Clovis Oncology make?

Clovis Oncology has a market capitalization of $508.19 million and generates $164.52 million in revenue each year. The biopharmaceutical company earns $-369,210,000.00 in net income (profit) each year or ($3.92) on an earnings per share basis.

What is Clovis Oncology's official website?

The official website for Clovis Oncology is www.clovisoncology.com.

Where are Clovis Oncology's headquarters?

Clovis Oncology is headquartered at 5500 FLATIRON PARKWAY SUITE 100, BOULDER CO, 80301.

How can I contact Clovis Oncology?

Clovis Oncology's mailing address is 5500 FLATIRON PARKWAY SUITE 100, BOULDER CO, 80301. The biopharmaceutical company can be reached via phone at 303-625-5000 or via email at [email protected]

This page was last updated on 7/26/2021 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here